Similar articles for PMID: 21493863

Year	Number of Results
1998	3
2001	1
2003	1
2004	3
2005	3
2006	4
2007	4
2008	8
2009	6
2010	11
2011	8
2012	5
2013	7
2014	9
2015	11
2016	6
2017	3
2018	6
2019	8
2020	9
2021	4
2022	2
2023	1
2024	0

1

Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.

Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC. Habashi JP, et al. Science. 2011 Apr 15;332(6027):361-5. doi: 10.1126/science.1192152. Science. 2011. PMID: 21493863 Free PMC article.

2

Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.

Cook JR, Clayton NP, Carta L, Galatioto J, Chiu E, Smaldone S, Nelson CA, Cheng SH, Wentworth BM, Ramirez F. Cook JR, et al. Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):911-7. doi: 10.1161/ATVBAHA.114.305150. Epub 2015 Jan 22. Arterioscler Thromb Vasc Biol. 2015. PMID: 25614286 Free PMC article.

3

Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.

Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, Lindsay ME, Kim D, Schoenhoff F, Cohn RD, Loeys BL, Thomas CJ, Patnaik S, Marugan JJ, Judge DP, Dietz HC. Holm TM, et al. Science. 2011 Apr 15;332(6027):358-61. doi: 10.1126/science.1192149. Science. 2011. PMID: 21493862 Free PMC article.

4

The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.

Verbrugghe P, Verhoeven J, Clijsters M, Vervoort D, Schepens J, Meuris B, Herijgers P. Verbrugghe P, et al. J Cardiovasc Pharmacol. 2018 Apr;71(4):215-222. doi: 10.1097/FJC.0000000000000560. J Cardiovasc Pharmacol. 2018. PMID: 29300219 Free PMC article.

5

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Habashi JP, et al. Science. 2006 Apr 7;312(5770):117-21. doi: 10.1126/science.1124287. Science. 2006. PMID: 16601194 Free PMC article.

6

miR-29b participates in early aneurysm development in Marfan syndrome.

Merk DR, Chin JT, Dake BA, Maegdefessel L, Miller MO, Kimura N, Tsao PS, Iosef C, Berry GJ, Mohr FW, Spin JM, Alvira CM, Robbins RC, Fischbein MP. Merk DR, et al. Circ Res. 2012 Jan 20;110(2):312-24. doi: 10.1161/CIRCRESAHA.111.253740. Epub 2011 Nov 23. Circ Res. 2012. PMID: 22116819

7

Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.

Naito T, Ma LJ, Yang H, Zuo Y, Tang Y, Han JY, Kon V, Fogo AB. Naito T, et al. Am J Physiol Renal Physiol. 2010 Mar;298(3):F683-91. doi: 10.1152/ajprenal.00503.2009. Epub 2009 Dec 30. Am J Physiol Renal Physiol. 2010. PMID: 20042458 Free PMC article.

8

Accelerated Marfan syndrome model recapitulates established signaling pathways.

Gensicke NM, Cavanaugh NB, Andersen ND, Huang T, Qian L, Dyle MC, Turek JW. Gensicke NM, et al. J Thorac Cardiovasc Surg. 2020 May;159(5):1719-1726. doi: 10.1016/j.jtcvs.2019.05.043. Epub 2019 May 31. J Thorac Cardiovasc Surg. 2020. PMID: 31272746 Free article.

9

Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-β-induced phosphorylation of ERK.

Wylie-Sears J, Levine RA, Bischoff J. Wylie-Sears J, et al. Biochem Biophys Res Commun. 2014 Apr 18;446(4):870-5. doi: 10.1016/j.bbrc.2014.03.014. Epub 2014 Mar 12. Biochem Biophys Res Commun. 2014. PMID: 24632204 Free PMC article.

10

Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.

Gambarin FI, Favalli V, Serio A, Regazzi M, Pasotti M, Klersy C, Dore R, Mannarino S, Viganò M, Odero A, Amato S, Tavazzi L, Arbustini E. Gambarin FI, et al. J Cardiovasc Med (Hagerstown). 2009 Apr;10(4):354-62. doi: 10.2459/JCM.0b013e3283232a45. J Cardiovasc Med (Hagerstown). 2009. PMID: 19430350 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

111 results

Results by year